PCSK9 as Predictor for Recurrent Cardiovascular Disease in Familial Hypercholesterolemia

European Journal of Preventive Cardiology - United Kingdom
doi 10.1177/2047487319886140
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Effect of Lipid-Lowering Treatment in Cardiovascular Disease Prevalence in Familial Hypercholesterolemia

Atherosclerosis
Cardiovascular MedicineCardiology
2019English

Angiotensin-Converting Enzyme DD Genotype and Cardiovascular Disease in Heterozygous Familial Hypercholesterolemia

Circulation
Cardiovascular MedicinePhysiologyCardiology
1998English

Homozygous Familial Hypercholesterolemia “Rare Disease”

Journal of Glycomics & Lipidomics
2014English

Sitosterolemia Presenting as Pseudohomozygous Familial Hypercholesterolemia

Clinical Medicine and Research
MedicineHome CareCommunity
2016English

Familial Hypercholesterolemia

Journal of Atherosclerosis and Thrombosis
BiochemistryInternal MedicineCardiovascular MedicineCardiology
2014English

Erectile Dysfunction as a Predictor of Cardiovascular Disease

International Journal of Impotence Research
Urology
2008English

Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm.

CJC Open
Cardiovascular MedicineCardiology
2019English

Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials

Journal of Pharmacy and Pharmaceutical Sciences
MedicinePharmacologyPharmaceutical Science
2017English

Familial Hypercholesterolemia and COVID-19: Triggering of Increased Sustained Cardiovascular Risk

Journal of Internal Medicine
Internal Medicine
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy